We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
-7.21%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.1B
AUM Growth
-$504M
Cap. Flow
-$227M
Cap. Flow %
-10.82%
Top 10 Hldgs %
55.38%
Holding
76
New
4
Increased
13
Reduced
26
Closed
8

Top Buys

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$39M
2
BSX icon
Boston Scientific
BSX
+$20.1M
3
BHVN icon
Biohaven
BHVN
+$10.8M
4
RGNX icon
Regenxbio
RGNX
+$9.92M
5
EVH icon
Evolent Health
EVH
+$7M

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$68.7M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$42.4M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$42.4M
4
FOLD
Amicus Therapeutics
FOLD
+$33.8M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$26.2M

Sector Composition

Rank Sector Weight
1 Healthcare 96.1%
2 Industrials 3.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZBH icon
76
Zimmer Biomet
ZBH
$17.7B
– –
-151,372
Closed -$22M
1 2 3
4

Similar funds

KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Redmile Group's Q3 2023 Portfolio in Review

As of Q3 2023, Redmile Group held 76 positions worth $2.1B, down 19% from $2.61B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Redmile Group withdrew a net $227M in Q3 2023, closing 8 positions and reducing 26 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $42.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Industrials.

Against the trend, Redmile Group opened a new position in RayzeBio, Inc. Common Stock worth $41.2M.

  • Redmile Group's largest Q3 2023 buy was RayzeBio, Inc. Common Stock: 1,857,706 shares worth $41.2M.
  • Redmile Group added most to Boston Scientific in Q3 2023, an estimated $20.1M increase.
  • Redmile Group's biggest Q3 2023 reduction was Krystal Biotech, cutting an estimated $68.7M.
  • Redmile Group fully exited BioMarin Pharmaceuticals in Q3 2023, selling an estimated $42.4M.
  • Redmile Group's ten largest holdings make up 55% of its $2.1B portfolio in Q3 2023.
  • Redmile Group opened 4 new positions and closed 8 in Q3 2023.
  • Redmile Group's portfolio value fell 19% quarter-over-quarter to $2.1B.

Based on Redmile Group's 13F filing for Q3 2023, filed 14 Nov 2023.